ArticleTranslational cancer research2026
A distinct form of colorectal cancer: signet ring cell carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal signet ring cell carcinoma (SRCC) is a rare histological subtype of colorectal cancer (CRC), accounting for about 1% of all cases. Due to its rarity, many pathological aspects of SRCC have not been fully clarified. This study set out to characterize the clinicopathology of SRCC and to create a superior nomogram, ultimately to inform treatment selection and prognosis with new evidence. Methods: The patients for our research were collected from the Surveillance, Epidemiology, and End Results (SEER) database. χ Results: A total of 49,405 patients were included, with 842 SRCC patients (1.7%) and 48,563 colorectal adenocarcinoma (COAD) patients (98.3%). In SRCC, patients were of younger age, more poorly differentiated tumor grade (62.71% Conclusions: SRCC is a distinct entity, and its unique clinicopathological features should be considered more in the diagnosis and treatment process. With LNR and treatment strategy taken into account, the nomogram model had better predictive ability and stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.